Skip to main content
. 2016 Nov 23;50(1):31–40. doi: 10.3892/ijo.2016.3778

Figure 2.

Figure 2

Correlation of STMN1 expression with clinicopathological parameter and prognosis of HSCC patients. (A) Representative images of STMN1 IHC staining in various differentiation types. (a and b) Well-differentiated, (c and d) Poor-differentiation (magnification, ×100 and ×400). (B) STMN1 IHC score was significantly higher in poor-differentiation type than that in well-differentiated type. Moreover, STMN1 IHC score was significantly correlated with clinical stages (C) tumor size (D) lymph node metastasis (E). (F) Relative STMN1 protein levels in HSCC tumor (T) and adjacent tissues (N) were explored by western blot analysis. (G) Relative STMN1 protein levels in FaDu cells. (H) Quantitative results of western blot analysis. (I and J) Kaplan-Meier survival curves showed that patients in the moderate/strong STMN1 expression group had significantly poorer prognosis than those in the negative/weak expression group (P=0.0019, P<0.0001). *P<0.05 **P<0.01, statistically significant. Data are expressed as the mean ± SD.